Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories

Thrombosis and Haemostasis

Volumn 116, Issue 1, 2016, Pages 50-57

  Smock, Kristi J ^a   Plumhoff, Elizabeth A ^b   Meijer, Piet ^c   Hsu, Peihong ^d   Zantek, Nicole D ^e   Heikal, Nahla M ^a   Van Cott, Elizabeth M ^f  

^a ARUP LABORATORIES   (United States)

^b MAYO CLINIC   (United States)

^c ECAT Foundation   (Netherlands)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Direct oral anticoagulants; Factor V Leiden; NASCOLA; Proficiency testing; Protein S

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN S; RIVAROXABAN; BLOOD CLOTTING FACTOR 5;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE MUTATION; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; PROTEIN S TEST; ACTIVATED PROTEIN C RESISTANCE; BLOOD; BLOOD ANALYSIS; EVALUATION STUDY; GENETICS; HUMAN; LABORATORY; NORTH AMERICA; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ACTIVATED PROTEIN C RESISTANCE; BLOOD CHEMICAL ANALYSIS; FACTOR V; HUMANS; LABORATORIES; NORTH AMERICA; PROTEIN S; PROTEIN S DEFICIENCY; RIVAROXABAN;

EID: 84977600784     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-12-0918     Document Type: Article

References (22)

1. Goodwin AJ, et al. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002; 126: 1349-1366.
2. Pintao MC, et al. Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. Blood 2013; 122: 3210-3219.
3. Marlar RA, Gausman JN. Protein S abnormalities: a diagnostic nightmare. Am J Hematol 2011; 86: 418-421.
4. Marlar RA, Gausman JN. Laboratory testing issues for protein C, protein S, and antithrombin. Int J Lab Hematol 2014; 36: 289-295.
5. Hepner M, Karlaftis V. Protein S. Methods Mol Biol 2013; 992: 373-381.
6. Dykes AC, et al. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-641.
7. Franchi F, et al. Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. Thromb Res 2013; 132: e152-157.
8. Makris M, et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000; 95: 1935-1941.
9. Moser KA, et al. Pitfalls in special coagulation testing: three illustrative case studies. Int J Lab Hematol 2013; 35: 334-338.
10. Libourel EJ, et al. Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a retrospective study. Blood Coagul Fibrinolysis 2005; 16: 135-140.
11. Gandrille S, et al. Protein S deficiency: a database of mutations--summary of the first update. Thromb Haemost 2000; 84: 918.
12. Favaloro EJ, et al. Laboratory investigation of thrombophilia: the good, the bad, and the ugly. Semin Thromb Hemost 2009; 35: 695-710.
13. Jennings I, et al. Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits. J Thromb Haemost 2003; 1: 1112-1114.
14. Brouwer JL, et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005; 128: 703-710.
15. Van Cott EM, et al. Protein S assays: an analysis of North American Specialized Coagulation Laboratory Association proficiency testing. Am J Clin Pathol 2005; 123: 778-785.
16. Mulder R, et al. Low cut-off values increase diagnostic performance of protein S assays. Thromb Haemost 2010; 104: 618-625.
17. Zoller B, et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
18. Press RD, et al. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002; 126: 1304-1318.
19. Mani H, et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013; 109: 127-136.
20. Hillarp A, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 2014; 12: 1545-1553.
21. Adcock DM, et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013; 139: 102-109.
22. Kim YA, et al. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol 2015; 37: e81-4.